Given the emerging interest in peptide-based cancer therapeutics, and recent advances in improving peptide stability and delivery [52,53], we propose that the sFZD7 peptide is a feasible therapeutic agent that can be used to specifically abolish the functional activity of FZD7 in HCC. Here, FZD7 is linked to hepatocellular carcinoma.